Get a Free Consultation
Artificial Intelligence Precision Oncology

SYNERGY-AI Based Precision Oncology Clinical Trial Matching

NEW YORK–(BUSINESS WIRE)–Massive Bio, Inc., a leader in providing simplified and affordable access to precision oncology to cancer patients treated at community-based oncology practices, announced today that the first patient has been enrolled in a global registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool powered by a virtual tumor board (VTB) program. This registry will assess its clinical impact on world-wide patients with advanced cancer to facilitate clinical trial enrollment (CTE), as well as financial impact.

The SYNERGY-AI registry is the first of its kind to combine artificial intelligence, genomic biomarkers and multi-variate analysis to accelerate clinical trial matching and promote access to promising cancer therapies. SYNERGY-AI is a part of Massive Bio’s global strategic collaboration with community-based oncology practices. Established in 2014, the goal of the collaboration is to promote precision oncology approaches at the point-of-care, and to ease access to clinical trials, while reducing patient and provider burden and overall cancer care costs.

“Today’s announcement marks a one-of-a-kind clinical program which utilizes a precision medicine approach to clinical trial matching that could potentially catalyze accelerated enrollment from a patient-driven perspective, while promoting access and innovation,” said Dr. Arturo Loaiza-Bonilla, MD, MSEd, Chief Medical Advisor and Co-Founder of Massive Bio. “Initiation of this study also represents a significant milestone for Massive Bio, as we have the opportunity to help over 1,500 patients to enroll in therapeutic cancer trials. Most importantly, we believe this program has the potential to change the paradigm of how we approach clinical trial screening and enrollment and help many more patients in the future.”

Read more about this article

Leave a Reply

Your email address will not be published. Required fields are marked *

Join our community
and receive our newsletter